CA2621564C — Pyridine derivatives and their use in the treatment of psychotic disorders
Assigned to Kandy Therapeutics Ltd · Expires 2014-06-03 · 12y expired
What this patent protects
Compounds are provided, which compounds are 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4] oxazin-8(1H)-yl] -3-pyridinyl } -N,2-dimethylpropanamide: (see above formula) or pharmaceutically acceptable…
USPTO Abstract
Compounds are provided, which compounds are 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4] oxazin-8(1H)-yl] -3-pyridinyl } -N,2-dimethylpropanamide: (see above formula) or pharmaceutically acceptable salts thereof, as well as uses of these compounds in therapy or treatment of disorders, including: psychotic disorders, including schizophrenia; depressive disorders, including bipolar disorders; and alcohol related disorders, including alcohol dependence.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.